Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Eur Acad Dermatol Venereol ; 22(5): 549-54, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18410617

RESUMO

BACKGROUND: Malignant nodular hidradenoma (MNH) is an infrequent, highly malignant, primary skin tumour derived from eccrine sweat glands. Most tumours occur in elderly individuals. MNH has very poor prognosis, high recurrence and a high rate of metastases. The best method of treatment is still unclear: radical surgical excision is widely used, and selective lymph node dissection is also suggested. The value of the adjuvant radiotherapy and chemotherapy has not been confirmed. PATIENTS AND TREATMENT: Seven MNH patients (4 men, 3 women, age 60-87 years) were treated between 1991 and 2007 in the Dermatology Unit of San Donato Hospital of Arezzo and in the Section of Dermatology of University of Siena, Italy. Tumours varied from 0.8 to 4.4 cm in size. All patients underwent local excision; five also had lymph node dissection. One patient underwent adjuvant radiotherapy, and three received chemotherapy. RESULTS: Six of seven patients died, with survival varying from 15 to 45 months. Distant metastases occurred in two patients. Survival time was inversely proportional to the size of the tumour. CONCLUSIONS: MNH is an aggressive tumour and should be diagnosed and excised as early as possible. Histological parameters are paramount, but correct diagnosis also calls for attention to clinical presentation and any history of recurrence or recent enlargement of long-standing lesions. In our experience, radiotherapy and chemotherapy do not seem to prolong survival.


Assuntos
Adenoma de Glândula Sudorípara/diagnóstico , Neoplasias Cutâneas/diagnóstico , Neoplasias das Glândulas Sudoríparas/diagnóstico , Adenoma de Glândula Sudorípara/patologia , Adenoma de Glândula Sudorípara/terapia , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Evolução Fatal , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Pele/patologia , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/terapia , Neoplasias das Glândulas Sudoríparas/patologia , Neoplasias das Glândulas Sudoríparas/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA